Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature.
Botticelli A, Fabbri A, Roberto M, Alesini D, Cirillo A, D'Auria G, Krasniqi E, Marrucci E, Muratore M, Pantano F, Pizzuti L, Portarena I, Rossi R, Scagnoli S, Marchetti P. Botticelli A, et al. Among authors: portarena i. Front Oncol. 2022 Feb 9;12:797157. doi: 10.3389/fonc.2022.797157. eCollection 2022. Front Oncol. 2022. PMID: 35223478 Free PMC article.
Current challenges in HER2-positive breast cancer.
Puglisi F, Fontanella C, Amoroso V, Bianchi GV, Bisagni G, Falci C, Fontana A, Generali D, Gianni L, Grassadonia A, Moscetti L, Portarena I, Rossi E, Marchetti P. Puglisi F, et al. Among authors: portarena i. Crit Rev Oncol Hematol. 2016 Feb;98:211-21. doi: 10.1016/j.critrevonc.2015.10.016. Epub 2015 Oct 31. Crit Rev Oncol Hematol. 2016. PMID: 26638862 Free article. Review.
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, Mentuccia L, Fabbri A, Barba M, Sanguineti G, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Aroldi F, Orlandi A, Moscetti L, Sergi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L, De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamagni C, Rubino D, Cortesi E, Magri V, Pomati G, Scagnoli S, Capomolla E, Kayal R, Scinto AF, Corsi D, Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carbognin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficorella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, Vici P. Pizzuti L, et al. Among authors: portarena i. J Cell Physiol. 2019 Jun;234(6):7708-7717. doi: 10.1002/jcp.27832. Epub 2018 Dec 10. J Cell Physiol. 2019. PMID: 30536609
CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives.
Roberto M, Astone A, Botticelli A, Carbognin L, Cassano A, D'Auria G, Fabbri A, Fabi A, Gamucci T, Krasniqi E, Minelli M, Orlandi A, Pantano F, Paris I, Pizzuti L, Portarena I, Salesi N, Scagnoli S, Scavina P, Tonini G, Vici P, Marchetti P. Roberto M, et al. Among authors: portarena i. Cancers (Basel). 2021 Jan 18;13(2):332. doi: 10.3390/cancers13020332. Cancers (Basel). 2021. PMID: 33477469 Free PMC article. Review.
Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression.
Ferroni P, Riondino S, Laudisi A, Portarena I, Formica V, Alessandroni J, D'Alessandro R, Orlandi A, Costarelli L, Cavaliere F, Guadagni F, Roselli M. Ferroni P, et al. Among authors: portarena i. Oncologist. 2016 Sep;21(9):1041-9. doi: 10.1634/theoncologist.2015-0462. Epub 2016 Jul 7. Oncologist. 2016. PMID: 27388232 Free PMC article.
Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt.
Formica V, Benassi M, Del Vecchio Blanco G, Doldo E, Martano L, Portarena I, Nardecchia A, Lucchetti J, Morelli C, Giudice E, Rossi P, Anselmo A, Sileri P, Sica G, Orlandi A, Santoni R, Roselli M. Formica V, et al. Among authors: portarena i. Med Oncol. 2018 May 2;35(6):83. doi: 10.1007/s12032-018-1141-4. Med Oncol. 2018. PMID: 29721745 Clinical Trial.
Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer.
Orsaria P, Chiaravalloti A, Caredda E, Marchese PV, Titka B, Anemona L, Portarena I, Schillaci O, Petrella G, Palombi L, Buonomo OC. Orsaria P, et al. Among authors: portarena i. Anticancer Res. 2018 Dec;38(12):6639-6652. doi: 10.21873/anticanres.13031. Anticancer Res. 2018. PMID: 30504372 Clinical Trial.
58 results